25 studies found for:    Ustekinumab | Open Studies
Show Display Options
Rank Status Study
1 Recruiting A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Conditions: Colitis, Ulcerative;   Inflammatory Bowel Diseases
Interventions: Drug: Placebo IV;   Drug: Placebo SC;   Drug: Ustekinumab IV;   Drug: Ustekinumab SC
2 Recruiting A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Ustekinumab IV;   Drug: Placebo Infusion;   Drug: Placebo SC;   Drug: Ustekinumab SC;   Other: Concomitant Medication
3 Recruiting An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than 6 to Less Than 12 Years of Age
Condition: Psoriasis
Interventions: Drug: Ustekinumab 0.75 mg/kg;   Drug: Ustekinumab 45 mg;   Drug: Ustekinumab 90 mg
4 Recruiting A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Naive Participants With Active Radiographic Axial Spondyloarthritis
Condition: Axial Spondyloarthritis
Interventions: Drug: Placebo;   Drug: Ustekinumab 45 mg;   Drug: Ustekinumab 90 mg;   Drug: Golimumab 50 mg
5 Recruiting A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis
Condition: Axial Spondyloarthritis
Interventions: Drug: Placebo;   Drug: Ustekinumab 45 mg;   Drug: Ustekinumab 90 mg;   Drug: Golimumab 50 mg
6 Recruiting An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis
Condition: Nonradiographic Axial Spondylitis, Ankylosing
Interventions: Drug: Group 1: Placebo;   Drug: Group 2: Ustekinumab 45 mg;   Drug: Group 3: Ustekinumab 90 mg
7 Recruiting Exploratory Study on Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With Type 1 Diabetes Mellitus
Condition: Type 1 Diabetes Mellitus
Intervention: Drug: INGAP Peptide, Ustekinumab
8 Recruiting The Difference of Microparticles in Patients With Psoriasis Vulgaris Who Received Stelara(Ustekinumab)
Condition: Psoriasis With Cell-derived Microparticles
Intervention: Drug: Ustekinumab
9 Recruiting Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
Condition: Plaque Psoriasis
Interventions: Drug: Secukinumab;   Drug: Ustekinumab
10 Not yet recruiting Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease
Condition: Behçet Disease
Intervention: Drug: Subcutaneous Ustekinumab
11 Recruiting Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
Conditions: CVID;   Enteropathy;   Chronic Diarrhea;   Maldigestion;   Malabsorption
Intervention: Biological: Ustekinumab
12 Unknown  A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis
Conditions: Scalp Psoriasis;   Plaque Psoriasis
Interventions: Drug: Ustekinumab;   Drug: Placebo
13 Recruiting Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)
Conditions: Psoriasis;   Cardiovascular Disease
Interventions: Drug: Ustekinumab;   Drug: Placebo
14 Recruiting A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis
Condition: Psoriatic Arthritis
Intervention: Drug: No Intervention
15 Recruiting Swiss Dermatology Network of Targeted Therapies (SDNTT)
Condition: Psoriasis
Interventions: Biological: Adalimumab;   Biological: Etanercept;   Biological: Infliximab;   Biological: Ustekinumab;   Drug: Cyclosporine A;   Drug: Fumaric acids;   Drug: Methotrexate;   Drug: Other anti-psoriatic systemic treatments
16 Recruiting BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
Condition: Psoriasis
Interventions: Drug: BI 655066;   Drug: placebo to ustekinumab;   Drug: USTEKINUMAB;   Drug: placebo to BI 655066
17 Recruiting BI 655066 Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
Condition: Psoriasis
Interventions: Drug: BI 655066;   Drug: placebo to ustekinumab;   Drug: ustekinumab;   Drug: placebo to BI 655066
18 Recruiting Stelara Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
Conditions: Psoriasis;   Pregnancy
Intervention:
19 Not yet recruiting Pre-Clinical (Alzheimers) Diagnosis PCD = Optimum Outcomes OO
Condition: Alzheimer Disease
Interventions: Drug: roflumilast;   Biological: ustekinumab
20 Recruiting Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis
Condition: Psoriasis
Interventions: Drug: etanercept;   Drug: ustekinumab;   Drug: cyclosporine

   Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results    Last Page
Indicates status has not been verified in more than two years